Skip to main content

UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.